Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900241 | 0.90 | ALDH1A1 (0.33) | MAPTALDH1A1KDM4EHPGDOGA | |
| SCHEMBL9899771 | 0.82 | ALDH1A1 (0.32) | MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL9900219 | 0.78 | POLB (0.32) | MEN1KMT2A | |
| SCHEMBL9900188 | 0.77 | MAPT (0.31) | MAPTALDH1A1KDM4E | |
| SCHEMBL2328452 | 0.75 | OGA (0.31) | OGA | |
| SCHEMBL9900106 | 0.75 | ALDH1A1 (0.36) | ALDH1A1KDM4EHPGDMEN1LMNA | |
| SCHEMBL9900144 | 0.75 | FPR2 (0.46) | ALDH1A1 | |
| SCHEMBL9899943 | 0.75 | SCN9A (0.35) | MAPTALDH1A1KDM4E | |
| SCHEMBL27917153 | 0.74 | TXNRD1 (0.33) | — | |
| SCHEMBL9899898 | 0.72 | FPR2 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649068-B1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8846733-B2 | Oxazolyl-methylether derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-09-30 | — | — | US | disclosed |
| EP-2649068-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-20130261159-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-03 | — | — | US | disclosed |
| CN-103261194-A | Oxazolyl-methyl ether derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD | 2013-08-21 | — | — | CN | disclosed |
| WO-2012077049-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261159-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX7, ADORA3, P2RX1 | MAPT 3502/4885ALDH1A1 792/4885KDM4E 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.